Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

TRACON Pharmaceuticals ends 1Q with $30.4M to fund its cancer drug trials

% of readers think this story is Fact. Add your two cents.


TRACON Pharmaceuticals Inc (NASDAQ:TCON) ended the first quarter of 2021 on March 31 with cash and equivalents of $30.4 million, which it said will fund its operations into the second half of 2022.

The company also noted that as of May 5, it has initiated 22 US clinical sites and enrolled more than 20 patients in the pivotal ENVASARC trial of single-agent envafolimab and envafolimab combined with Yervoy, which has triggered the initial Data Monitoring Committee review of safety data from each cohort.

“We continue to be pleased with the pace of enrollment in the pivotal ENVASARC trial and remain on track to deliver interim data in the second half of this year and final data in 2022, CEO Dr Charles Theuer said in a statement.

READ: TRACON Pharmaceuticals driving the development of targeted therapies for cancer via collaborations

“We have now initiated 22 sites and have enrolled more than 20 patients which has triggered the initial Data Monitoring Committee review of safety data from each cohort, which we expect later this quarter,” Dr Theuer added.

In April, TRACON resubmitted its Orphan Drug Designation application to the US Food and Drug Administration (FDA) in response to a request for preclinical or clinical evidence of activity for its clinical-stage drug envafolimab for treating sarcoma. It expects correspondence from the FDA this quarter based on the amended application.

The company also outlined some other key upcoming milestones, including:

  • Orphan Drug Designation for envafolimab in soft tissue sarcoma from the FDA in 1H 2021
  • Independent Data Monitoring Committee review of ENVASARC safety data in 1H 2021
  • American Society of Clinical Oncology (ASCO) presentation of ENVASARC pivotal trial design in 1H 2021
  • ASCO presentation of TJ004309 Phase 1 data in 1H 2021
  • Interim ENVASARC efficacy and safety data in 2H 2021
  • Request FDA breakthrough therapy designation or Fast Track designation for envafolimab in 2H 2021
  • Decision on the envafolimab New Drug Application (NDA) in MSI-H/dMMR cancer that is under priority review by the Chinese National Medical Products Administration (NMPA)

TRACON has positioned itself as a collaboration partner that leads the regulatory filings, clinical trials, as well as US commercialization of best-in-class drug candidates, as an alternative to expensive contract research organization (CRO) based development.

Contact Sean at [email protected]

Story by ProactiveInvestors



Source: http://www.proactiveinvestors.com/companies/news/948634/tracon-pharmaceuticals-ends-1q-with-304m-to-fund-its-cancer-drug-trials-948634.html


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!


Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST


Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.

Report abuse
Loading...

    Comments

    Your Comments
    Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

    MOST RECENT
    Load more ...

    SignUp

    Login

    Newsletter

    Email this story
    Email this story

    If you really want to ban this commenter, please write down the reason:

    If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.